Introduction
============

*Acinetobacter baumannii* is an aerobic Gram-negative coccobacillus \[[@B1]\]. It causes nosocomial pneumonia, especially in patients on mechanical ventilation or after treatment with broad-spectrum antibiotics \[[@B1][@B2]\]. Interestingly, community-acquired pneumonia (CAP) caused by *A. baumannii* has a higher mortality rate than that of hospital-acquired pneumonia (HAP), although CAP caused by *A. baumannii*, especially multi-drug resistant (MDR) *A. baumannii*, is rare \[[@B3]\]. Recently, MDR *A. baumannii* has increased as an emerging problem because of restricted therapeutic options \[[@B4]\]. Here, we report the first case of CAP caused by MDR *A. baumannii* in Korea in a 78-year-old man.

Case report
===========

A 78-year-old man presented to the emergency department with dyspnea and fever for 6 hours. He was not currently employed and had no history of cigarette smoking or alcohol ingestion. He had no underlying disease. Besides, he had no hospital admission, antimicrobial use history and healthcare institution visiting record in 1 year. On admission, he appeared acutely ill. His blood pressure was 104/57 mmHg, respiratory rate 20 breaths per minute, pulse rate 110 beats per minute, and body temperature 38.2°C. A regular heart rhythm was observed. There were coarse breath sounds with crackles in the right lung field.

The laboratory results were as follows: white blood cell count 3,900/mm^3^ (72.5% neutrophils, 20.4% lymphocytes, 4.7% monocytes, 2.82% eosinophils), hemoglobin 12.2 g/dL, platelet count 197,000/mm^3^, C-reactive protein 1.24 mg/dL, blood urea nitrogen 28.2 mg/dL, creatinine 1.24 mg/dL, aspartate aminotransferase 16 UI/L, alanine aminotransferase 10 IU/L, total bilirubin 0.9 mg/dL, total protein 6.0 g/dL, and albumin 3.5 g/dL. The arterial blood gas analysis breathing room air was pH 7.44, pCO~2~ 24.1 mmHg, pO~2~ 59.0 mmHg, HCO~3~^--^ 17 mmol/L, and O~2~ saturation 87%. A plain chest radiograph showed patchy consolidations in the right middle and lower lobes ([Fig. 1A](#F1){ref-type="fig"}). Chest computed tomography (CT) showed lobar pneumonia in the right middle and lower lobes ([Fig. 2A](#F2){ref-type="fig"}). He was diagnosed with CAP. Intravenous piperacillin/tazobactam and ciprofloxacin were administered empirically.

![Chest radiography. **(A)** The chest radiograph on admission showed lobar pneumonia in the right upper and middle lobes. **(B)** On the 48^th^ day after admission, the chest radiograph showed improvement in the consolidations of the right and middle lobes.](ic-49-297-g001){#F1}

![Chest computed tomography (CT). **(A)** On admission, CT showed lobar pneumonia in the right upper and middle lobes with a parapneumonic effusion. **(B)** At the 48^th^ day after admission, CT showed improvement in the consolidations of the right upper and middle lobes.](ic-49-297-g002){#F2}

Five hours after admission, his respiratory distress worsened, and he was treated with oxygen at 6 L/min via mask. On the second day after admission, intravenous teicoplanin was administered because of a persistent fever. On the third day, *A. baumannii* was identified in cultures of both sputum and in two of three pairs of blood samples taken on admission. *A. baumannii* was identified using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS, Bruker Daltonics GmbH, Bremen, Germany) on a Microflex spectrometer (Bruker Daltonics GmbH, Germany). Antimicrobial susceptibilities were determined using VITEK-2 system (bioMerieux, Marcy I\'Etoile, France). The bacterial isolate was resistant to multiple drugs, except colistin, tigecycline, minocycline, amikacin, and gentamicin ([Table 1](#T1){ref-type="table"}). Therefore, the antibiotics were changed to intravenous colistin and oral minocycline.

###### The antibiotic susceptibility of the *Acinetobacter baumannii* isolate

![](ic-49-297-i001)

  Antibiotic                      MIC    Susceptibility
  ------------------------------- ------ ----------------
  Ampicillin/sulbactam            ≥32    R
  Ceftazidime                     4      R
  Ciprofloxacin                   ≥4     R
  Colistin                        ≤0.5   S
  Cefepime                        ≥64    R
  Cefotaxime                      32     I
  Gentamicin                      ≤1     S
  Imipenem                        ≥16    R
  Levofloxacin                    ≥8     R
  Meropenem                       ≥16    R
  Minocycline                     ≤1     S
  Piperacillin                    ≥128   R
  Piperacillin/tazobactam         ≥128   R
  Trimethoprim/sulfamethoxazole   160    R
  Tigecycline                     ≤0.5   S

MIC, minimum inhibitory concentration; R, resistant; I, intermediate resistance; S, susceptible

On the 6th day after admission, his vital signs stabilized and the fever subsided. Follow-up chest radiography and CT showed improved consolidation. No *A. baumannii* grew in the follow-up blood cultures. On the 26th day after admission, because of colistin-induced nephropathy, the antibiotics were switched to tigecycline. On the 48th day after admission, the chest radiograph and chest CT showed that the pneumonia had improved ([Fig.1B](#F1){ref-type="fig"} and [2B](#F2){ref-type="fig"}). The patient was discharged on day 56 and followed as an outpatient with no significant complications.

Discussion
==========

Organisms in the genus *Acinetobacter* were isolated and first described by the microbiologist Beijerinck in 1911 \[[@B2]\]. *A. baumannii* is an aerobic Gram-negative coccobacillus that occurs in fresh water and soil \[[@B1]\]. *A. baumannii* is regarded as a significant pathogen causing nosocomial pneumonia \[[@B1][@B2]\]. By contrast, community-onset *A. baumannii* infection is uncommon and usually occurs in patients with solid tumor, prior receipt of antimicrobial agents within 30 days and central venous catheterization \[[@B5]\]. Especially CAP caused by *A. baumannii* tends to progress rapidly to a fulminate clinical course \[[@B1][@B2][@B3][@B6]\]. Recently, the incidence of carbapenem-resistant *A. baumannii* has increased \[[@B7][@B8]\].

Five cases of CAP caused by *A. baumannii* have been reported in Korea; in all cases, *A. baumannii* was identified in sputum cultures, blood cultures, or biopsy. Fortunately, the *A. baumannii* was susceptible to piperacillin/tazobactam, ceftazidime, cefepime, meropenem, and tobramycin \[[@B9][@B10][@B11][@B12][@B13]\]. In our case, susceptibility tests showed that the *A. baumannii* was resistant to piperacillin/tazobactam, ceftazidime, cefepime, imipenem, meropenem, and tobramycin but susceptible to colistin, tigecycline, minocycline, amikacin, and gentamicin.

Although this is the first reported case of CAP caused by MDR *A. baumannii* in Korea, it is expected to increase with the incidence of MDR *A. baumannii*. MDR *A. baumannii* should be considered if empirical antibiotics do not work in CAP. Recommended empirical antibiotics for CAP caused by *A. baumannii* include anti-pseudomonal penicillins, ciprofloxacin, aminoglycoside, and imipenem \[[@B14][@B15][@B16]\]. However, *A. baumannii* resistance to carbapenem has increased recently, limiting the treatment options \[[@B4]\]. MDR *A. baumannii* has few treatment options and a poor prognosis, although colistin, tigecycline, or minocycline are options \[[@B16][@B17][@B18]\]. Our patient responded to colistin (with minocycline) and tigecycline, despite a long treatment period.

This case is an example of the successful treatment of CAP caused by MDR *A. baumannii*, in a patient without medical comorbidities, and is the first reported case of CAP caused by MDR *A. baumannii* in Korea. MDR *A. baumannii* should be considered as a pathogen causing community-acquired pneumonia, and further epidemiological studies are needed to control infection.
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